

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4524104

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	IMPRIMIS PHARMACEUTICALS, INC.	07/10/2017
RECEIVING PARTY DATA		
Name:	ETON PHARMACEUTICALS, INC.	
Street Address:	21925 FIELD PARKWAY	
Internal Address:	SUITE 235	
City:	DEER PARK	
State/Country:	ILLINOIS	
Postal Code:	60010	
PROPERTY NUMBERS Total: 3		
	Property Type	Number
	Application Number:	15620430
	Application Number:	14307773
	Application Number:	61836535
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	ajoseph@lathropgage.com, bostonpatent@lathropgage.com	
Correspondent Name:	LATHROP & GAGE LLP	
Address Line 1:	28 STATE STREET	
Address Line 2:	SUITE 700	
Address Line 4:	BOSTON, MASSACHUSETTS 02109	
ATTORNEY DOCKET NUMBER:	591897: IPI-002CIP	
NAME OF SUBMITTER:	SEAN M. COUGHLIN	
SIGNATURE:	/Sean M. Coughlin/	
DATE SIGNED:	07/27/2017	
Total Attachments: 3		
source=591897_Assignment_from_Imprimis_to_Eton#page1.tif		
source=591897_Assignment_from_Imprimis_to_Eton#page2.tif		
source=591897_Assignment_from_Imprimis_to_Eton#page3.tif		

ASSIGNMENT

WHEREAS, **Imprimis Pharmaceuticals, Inc.**, a corporation duly organized under the laws of the United States of America, and having its principal place of business at 12626 High Bluff Drive, Suite 105, San Diego, California 92130, U.S.A., is the owner by assignment of applications for Letters Patent of the United States entitled:

**PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE
DERIVATIVES, AND THEIR USE**

**U.S. Serial No.: 15/620,430, filed June 12, 2017,
International Application No. PCT/US14/42945, filed June 18, 2014,
U.S. Serial No.: 14/307,773, filed June 18, 2014,
U.S. Serial No.: 61/836,535, filed June 18, 2013, and
Canadian Application No. 2,915,814, filed June 18, 2014; and**

WHEREAS, **Eton Pharmaceuticals, Inc.**, a corporation duly organized under the laws of the United States of America, and having its principal place of business at 21925 Field Parkway, Suite 235, Deer Park, IL 60010, U.S.A., is desirous of acquiring all rights, title and interests in and to said invention, said application(s), and in and to any and all Letters Patent which may be granted for or upon said invention and application(s) in the United States of America and anywhere in the world.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt of which is hereby acknowledged, **Imprimis Pharmaceuticals, Inc.**, has sold, assigned and transferred, and by these presents do sell, assign and transfer, unto said **Eton Pharmaceuticals, Inc.**, the full and exclusive right, title and interest, throughout the world, in, to and under the following:


(a) said invention as fully set forth and described in the specification prepared, and executed by us preparatory to obtaining Letters Patent of the United States therefor;

- (b) said application(s);
- (c) any and all refilings, divisions, continuations and continuations-in-part of said application(s);
- (d) any and all Letters Patent of the United States of America which may issue from said application(s), refilings, divisions, continuations and continuations-in-part;
- (e) any and all reissues and reexaminations of said Letters Patent of the United States of America;
- (f) any and all application(s) for Letters Patent upon said invention which may hereafter be filed in any and all countries foreign to the United States of America;
- (g) any and all refilings, divisions and continuations of said foreign-filed application(s);
- (h) any and all Letters Patent of countries foreign to the United States of America which may issue from the said foreign-filed application(s), refilings, divisions and continuations; and
- (i) any and all extensions of, and additions to, said Letters Patent of countries foreign to the United States of America.

Imprimis Pharmaceuticals, Inc., further agrees that upon request we will provide promptly all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to **Eton Pharmaceuticals, Inc.** or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application(s), said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

All of the above shall be held and enjoyed by said **Eton Pharmaceuticals, Inc.** for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said Letters Patent may be granted, and we hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.

7-10-2017
Date



Mark Baum, CEO for Imprimis Pharmaceuticals, Inc.